ArticleBritish journal of cancer2022

First-in-human phase 1 dose-escalation study of CAN04, a first-in-class interleukin-1 receptor accessory protein (IL1RAP) antibody in patients with solid tumours.

Debbie Robbrecht et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.